Myriad myRisk™ Hereditary Cancer Testing
Hereditary Cancer Testing
As a leader in the field of Hereditary Cancer Testing, Embry Women’s Health specializes in bringing the benefits of 25-gene panel testing to everyone.
Myriad myRisk™ Hereditary Cancer is a scientific advancement revolutionizing hereditary cancer testing. Blending both genetic test status AND personal cancer family history, Myriad myRisk hereditary cancer panel represents the next generation of hereditary cancer risk testing. Myriad myRisk identifies elevated risk for 8 important cancers by analyzing multiple, clinically significant genes.
Why Hereditary Cancer Panels?
Redefines the standard of care in hereditary cancer risk assessment through increased clinical sensitivity.
Why Myriad myRisk™?
Provides accurate knowledge of cancer risk and clear direction for patient care.
Myriad has a lifetime commitment to patients and providers.
Hereditary cancer panel testing optimizes patient care through increased clinical sensitivity (mutation detection). Testing a broader number of genes associated with multiple cancer risks increases clinical sensitivity. For example, many patients have personal and family history that may be explained by more than one syndrome. One patient may meet Lynch syndrome criteria and another may meet HBOC syndrome criteria. However, there are a significant number of patients that meet criteria for both Lynch and HBOC syndromes, among other risks.
Retrospective analysis of patients recorded at Myriad (2006-2013)
6.9% of patients appropriate for HBOC testing also meet Lynch criteria 30% of patients appropriate for Lynch testing also meet HBOC criteria
Myriad myRisk™ Hereditary Cancer increases mutation detection by 40-50% in patients appropriate for HBOC or Lynch testing.
The following case study illustrates a patient with a complex family history of cancer. A well designed hereditary cancer panel test will assess multiple genes with syndromic overlap, reducing the complexity of test selection so you can focus on optimizing medical management for your patient.
myRisk Test Report
Myriad myRisk™ provides accurate knowledge of cancer risk and clear direction for patient care. The revolutionary myRisk test report summarizes societal guidelines to optimize your medical management decisions for positive and negative results using gene and family history analysis.
Test reports begin with a myRisk Genetic Result, providing the diagnosis and information on any clinically significant mutations identified. Positive results are highlighted in red. Negative results are highlighted in green. Variants of Uncertain Significance are noted on the report and will be evaluated through Myriad’s myVision™ variant classification program.
The second part of the report, the myRisk Management Tool provides test and patient summary information, cancer risks, management guidance, and information for your patient’s family.
Genes selected for Myriad myRisk™ satisfy these criteria:
- Cancer Focus
- Hereditable contribution
- Association with overlapping syndromes
- Cancer risk is at least 2-3 times the general population
- Clinically Significant
- Based on increased cancer risk from societal guidelines or determined by multiple studies
- Change in management inferred based on risk level
Each gene tested with Myriad myRisk links to one or more of eight cancer sites: Breast, Ovarian, Colorectal, Endometrial, Melanoma, Pancreatic, Gastric, and Prostate. Myriad myRisk simplifies the test selection process by providing you the most comprehensive hereditary cancer panel test with clinically significant results. Be confident you are testing for the primary clinically significant genes associated with your patients’ risk.